These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23028032)

  • 1. Failure to control progression of rheumatoid arthritis after a decade of biologic therapy.
    Scheinberg M; Filippi RZ; Hands R; Pitzalis C
    J Rheumatol; 2012 Oct; 39(10):2049-50. PubMed ID: 23028032
    [No Abstract]   [Full Text] [Related]  

  • 2. Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis.
    Hazlewood GS; Barnabe C; Barr SG; Martin L
    J Clin Rheumatol; 2012 Dec; 18(8):416-8. PubMed ID: 23188208
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach.
    Devine EB; Alfonso-Cristancho R; Sullivan SD
    Pharmacotherapy; 2011 Jan; 31(1):39-51. PubMed ID: 21182357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
    D'Arcy CA; Willkens RF
    J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172
    [No Abstract]   [Full Text] [Related]  

  • 5. Back to the future: the managed care approach to rheumatoid arthritis.
    Sidorov J
    Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the drug treatment of rheumatoid arthritis.
    Mota LM; Cruz BA; Brenol CV; Pereira IA; Rezende-Fronza LS; Bertolo MB; Freitas MV; Silva NA; Louzada-Junior P; Giorgi RD; Lima RA; Bernardo WM; Pinheiro Gda R;
    Rev Bras Reumatol; 2013 Apr; 53(2):158-83. PubMed ID: 23856794
    [No Abstract]   [Full Text] [Related]  

  • 7. The risk of infections with biologic therapies for rheumatoid arthritis.
    Furst DE
    Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid arthritis initial therapy: unanswered questions.
    O'Dell J
    J Rheumatol Suppl; 2005 Jan; 72():14-6. PubMed ID: 15660457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of parenteral methotrexate significantly reduces the need for biological therapy.
    Bharadwaj A; Agrawal S; Batley M; Hammond A
    Rheumatology (Oxford); 2008 Feb; 47(2):222. PubMed ID: 18056146
    [No Abstract]   [Full Text] [Related]  

  • 11. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):283-8. PubMed ID: 21595176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 13. Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs.
    Secchiero P; Corallini F; Castellino G; Bortoluzzi A; Caruso L; Bugatti S; Bosco R; Montecucco M; Trotta F
    J Rheumatol; 2010 Jul; 37(7):1461-6. PubMed ID: 20472926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?
    Huizinga TW; Landewé RB
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):2-3. PubMed ID: 16932617
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations for the therapeutics of methotrexate in rheumatoid arthritis.
    Murphy G; Coughlan R; Devlin J; FitzGerald O; McCarthy G
    Ir Med J; 2009 Jun; 102(6):170-2. PubMed ID: 19722351
    [No Abstract]   [Full Text] [Related]  

  • 16. Tailor-made therapy in rheumatoid arthritis: fact or fiction?
    Haroon N; Misra R; Aggarwal A
    Isr Med Assoc J; 2008 Feb; 10(2):139-41. PubMed ID: 18432029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis.
    Hall SJ; Hickling P
    J Clin Rheumatol; 2007 Feb; 13(1):54. PubMed ID: 17278957
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategies for the management of rheumatoid arthritis.
    Wilkie WS; Schwieterman P
    Orthopedics; 2012 Feb; 35(2):125-30. PubMed ID: 22300992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key randomized trials of single agents in early rheumatoid arthritis.
    van de Putte LB
    J Rheumatol Suppl; 2002 Nov; 66():13-9. PubMed ID: 12435164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.